Engineering host cell lines to reduce terminal sialylation of secreted antibodies

mAbs

Volumn 2, Issue 5, 2010, Pages 519-527

  Naso, Michael F ^a   Tam, Susan H ^a   Scallon, Bernard J ^a   Raju, T Shantha ^a  

^a CENTOCOR INC   (United States)

Author keywords

ADCC; Antibodies; CDC; Cells; Effector functions; Fc receptors; Glycans; IgGs; Oligosaccharides; Proteases; Sialic acid; Sialidase

Indexed keywords

AMPICILLIN; ANTIBODY; FC RECEPTOR; GLYCAN; NEOMYCIN; RECOMBINANT ANTIBODY; SIALIC ACID; SIALIDASE; SIALIDASE A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTHROBACTER; ARTHROBACTER UREAFACIENS; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; GENETIC ENGINEERING; GENETIC HETEROGENEITY; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; SIALYLATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ARTHROBACTER; BACTERIAL PROTEINS; BASE SEQUENCE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOSYLATION; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; PLASMIDS; POLYSACCHARIDES; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSFECTION;

EID: 77958531332     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.13078     Document Type: Article

References (23)

1. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997; 15:26-32.
2. Raju TS. Terminal sugars of Gc glycans influence antibody effector functions of IgGs. Curr Opin Immun 2008; 20:471-8.
3. Raju TS. Glycosylation variations with expression systems and their impact on biological activity of therapeutic immunoglobulins. BioProcess Int 2003; 1:44-53.
4. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-13. (Pubitemid 47475656)
5. Satoh M, Lida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1161-73.
6. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immun 2007; 44:1525-34.
7. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3. (Pubitemid 44201145)
8. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-6.
9. Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009; 19:936-49.
10. Ngantung FA, Miller PG, Brunshett FR, Tang GL, Wang DI. RNA interference of sialidase improves glycoprotein sialic acid content consistency. Biotech Bioeng 2006; 95:106-19.
11. Winter AJ, Comis SD, Osborne MP, Tarlow MJ, Stephen J, Andrew PW, et al. A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. Infect Imm 1997; 65:4411-8.
12. Raju TS, Scallon B. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnol Prog 2007; 23:964-71. (Pubitemid 47255085)
13. Warner TG. Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting. Glycobiology 1999; 9:841-50.
14. Anumula KR. High-sensitivity and high-resolution methods for glycoprotein analysis. Anal Biochem 2000; 283:17-26.
15. Raju TS, Scallon BJ. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 2006; 341:797-803.
16. Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 2006; 58:707-22. (Pubitemid 44255854)
17. Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 2005; 68:283-91. (Pubitemid 41159998)
18. Chen P, Harcum SW. Effects of eleveated ammonium on glycosylation gene expression in CHO cells. Met Eng 2006; 8:123-32.
19. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgGs: evidence for the species-specific sialylaiton and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10:477-86.
20. Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function and expression. Physiol Rev 1995; 75:591-609.
21. Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 2007; 87:851-7.
22. Achyuthan KE, Achyuthan AM. Comparative enzymology, biochemistry and pathophysiology of human exo-α-sialidases (neuraminidases). Comp Biochem Physiol 2001; 129:29-64.
23. Christensen S, Egebjerg J. Cloning, expression and characterization of a sialidase gene from Arthrobacter ureafaciens. Biotechnol Appl Biochem 2005; 41: 225-31. (Pubitemid 40839595)